AR and Familial prostate cancer: Alternatively small molecules targeting the RBP NONO have been developed to relocate and trap this RBP in nuclear foci by stabilizing protein-RNA interaction, effectively reducing the expression of the androgen receptor in prostate cancer cells [227].